Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (61)	7/5/2002 11:53:30 AM
From: RWReeves	Read Replies (3) \| Respond to of 684

Hi Mike, the sector sure marches to the beat of a different drum. Trouble has been finding out which one. Your selection probably better than most... Back OT, ALKS plummets to the rolls of the BTFLTCV if I read the 10Q correctly with the adjustments for the consolidation backed out. I was surprised to see it roundly pole-axed for a FDA rebuff of all things PRE-clinical data. That should certainly be fixable for an already approved drug. With the various collaborations this looks pretty cheap. I also noticed VPHM now in the dollar daze. I can't understand why they never jumped on the meningitis data. There is a product in there calling to get out. Meteoric fall from the 60's probably makes most shy to even approach the hot cinders however. Bought some of both this week. Been some great nominations lately and fodder for some solid DD to be done, certainly. RWR